ENLV — Enlivex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $27.99m
- $4.56m
- 20
- 34
- 17
- 13
Annual cashflow statement for Enlivex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.38 | -11.8 | -14.5 | -31.1 | -29.1 |
| Depreciation | |||||
| Non-Cash Items | 1.1 | 0.837 | -2.26 | 5.53 | 2.28 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.04 | -0.306 | -1.36 | 0.804 | 2.43 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -7.04 | -11 | -17.5 | -24 | -23.5 |
| Capital Expenditures | -0.193 | -1.02 | -1.63 | -8.12 | -0.236 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -6.17 | -20 | -36.8 | 70.6 | -25.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -6.36 | -21 | -38.4 | 62.5 | -26 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 8.31 | 33.1 | 61 | 0.15 | 0.36 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.27 | 1.49 | 4.62 | 38.7 | -49.1 |